Phase II study of Neoadjuvant chemotherapy with Gemcitabine and S1 (GS therapy) for resectable pancreatic carcinoma (NAC GS3)

Trial Profile

Phase II study of Neoadjuvant chemotherapy with Gemcitabine and S1 (GS therapy) for resectable pancreatic carcinoma (NAC GS3)

Completed
Phase of Trial: Phase II

Latest Information Update: 04 Oct 2017

At a glance

  • Drugs Gemcitabine (Primary) ; Gimeracil/oteracil/tegafur (Primary)
  • Indications Pancreatic cancer
  • Focus Therapeutic Use
  • Most Recent Events

    • 03 Oct 2017 Status changed from active, no longer recruiting to completed.
    • 23 Jan 2013 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top